WuXi XDC Cayman
WuXi XDC Cayman Inc. is a China-based contract research, development, and manufacturing organization (CRDMO) focused on antibody-drug conjugates (ADCs) and bioconjugates. The company provides end-to-end services encompassing payload-linker synthesis, conjugation development, analytical testing, and commercial-scale cGMP manufacturing. Its integrated platforms support global biopharmaceutical partners from early-stage discovery through to clinical and commercial supply. Primary revenue is derived from contract development fees, milestone payments, and commercial manufacturing volume orders. WuXi XDC holds a market-leading global position as a specialized contract provider for complex ADC therapies. The company is headquartered in Wuxi, China, and its shares are listed on the Stock Exchange of Hong Kong.
26 of the funds FundTelligence covers report a position in WuXi XDC Cayman.
- Legal name
- WuXi XDC Cayman Inc
- Sector
- Health Care
- Country
- China
- Funds holding it
- 26
Funds holding WuXi XDC Cayman
- Schroder ISF All China Equity — Schroders · 1.58 % (full portfolio disclosed, June 2026)
- Schroder ISF Global Emerging Markets Smaller Companies — Schroders · 1.52 % (full portfolio disclosed, June 2026)
- Nordea Chinese Equity Fund — Nordea Funds · 1.36 % (full portfolio disclosed, September 2026)
- Nordea China — Nordea Funds · 1.35 % (full portfolio disclosed, September 2026)
- Schroder ISF China Opportunities — Schroders · 1.27 % (full portfolio disclosed, June 2026)
- BNP China Equity — BNP Paribas · 1.26 % (full portfolio disclosed, June 2026)
- Schroder ISF Emerging Markets Equity Alpha — Schroders · 1.24 % (full portfolio disclosed, June 2026)
- Schroder ISF Global Emerging Market Opportunities — Schroders · 1.23 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 26 funds holding it.